ICIs are typical immunotherapies that activate anti-tumor immunity by inhibiting negative regulatory receptors such as PD-1 and cytotoxic T lymphocyte antigen 4(CTLA4) [11]. This evidence concerns the gene PDCD1 and neoplasm.